Hindustan Bio Sciences Ratios

Hindustan Bio Sciences Ltd Ratios

The Hindustan Bio Sciences Ltd Ratios page provides a complete fundamental analysis of Hindustan Bio Sciences Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Hindustan Bio Sciences Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Hindustan Bio Sciences Ltd (NSE: , BSE: 532041) is currently trading at ₹7.80, with a market capitalization of ₹79.96M. As a major player in the Health technology sector and Pharmaceuticals: major industry, Hindustan Bio Sciences Ltd remains a key stock for fundamental analysis using Hindustan Bio Sciences Ltd Ratios.

Hindustan Bio Sciences Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Hindustan Bio Sciences Ltd P/E ratio currently stands at 71.08, making it one of the most tracked metrics in Hindustan Bio Sciences Ltd Ratios.

Historically, the Hindustan Bio Sciences Ltd P/E ratio has shown strong fluctuations:

• 2024: 71.08
• 2023: 129
• 2022: 0
• 2021: 0
• 2020: 0

The decline in Hindustan Bio Sciences Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Hindustan Bio Sciences Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 7.91.

Historical P/B trend:

• 2024: 7.91
• 2023: 9.24
• 2022: 7.30
• 2021: 5.50

Hindustan Bio Sciences Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Hindustan Bio Sciences Ltd P/S ratio currently stands at 8.80, an important part of Hindustan Bio Sciences Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 8.80
• 2023: 7.08
• 2022: 6.04
• 2021: 10.05

The rising Hindustan Bio Sciences Ltd P/S ratio indicates improved revenue valuation by investors.

Hindustan Bio Sciences Ltd Price to Cash Flow Ratio (P/CF)

The Hindustan Bio Sciences Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 264.02.

Historical Hindustan Bio Sciences Ltd Price to Cash Flow Ratio:

• 2024: 264.02
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 5.51

The rising Hindustan Bio Sciences Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Hindustan Bio Sciences Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Hindustan Bio Sciences Ltd EV currently stands at ₹96.49M, representing the total company valuation including debt.

Historical EV trend:

• 2024: 96.49M
• 2023: 99.53M
• 2022: 78.13M
• 2021: 64.83M

Hindustan Bio Sciences Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Hindustan Bio Sciences Ltd EV/EBITDA ratio is currently 94.51, a key metric in Hindustan Bio Sciences Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 94.51
• 2023: 165.81
• 2022: 0
• 2021: 0

Stable Hindustan Bio Sciences Ltd EV/EBITDA indicates balanced valuation.

Hindustan Bio Sciences Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Hindustan Bio Sciences Ltd D/E ratio is currently 2.77, reflecting leverage and financial stability.

Historical D/E:

• 2024: 2.77
• 2023: 3.18
• 2022: 3.29
• 2021: 2.75

Higher D/E ratio indicates rising financial risk.

Return on Equity (ROE %)

The Hindustan Bio Sciences Ltd ROE currently stands at 11.78%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 11.78
• 2023: 7.43
• 2022: -5.28
• 2021: -49.49

Hindustan Bio Sciences Ltd maintains stable profitability levels.

Hindustan Bio Sciences Ltd Ratios Analysis Summary

The Hindustan Bio Sciences Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Hindustan Bio Sciences Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Hindustan Bio Sciences Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.